biostudies-literatureErcan-Herbst EAbbVie Deutschland192https://www.ebi.ac.uk/biostudies/studies/S-EPMC6892178biostudies-literatureUnknown7(1)Tau is a microtubule-binding protein that can receive various post-translational modifications (PTMs) including phosphorylation, methylation, acetylation, glycosylation, nitration, sumoylation and truncation. Hyperphosphorylation of tau is linked to its aggregation and the formation of neurofibrillary tangles (NFTs), which are a hallmark of Alzheimer's disease (AD). While more than 70 phosphorylation sites have been detected previously on NFT tau, studies of oligomeric and detergent-soluble tau in human brains during the early stages of AD are lacking. Here we apply a comprehensive electrochemiluminescence ELISA assay to analyze twenty-five different PTM sites as well as tau oligomerization in control and sporadic AD brain. The samples were classified as Braak stages 0-I, II or III-IV, corActa neuropathologica communicationsA post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain.PMC6892178n.a.Behrendt APrat Oriol NSchondorf DCErcan-Herbst EEhrnhoefer DEWeber CEhrig JKlaus BGomez Ramos BfalseA post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain.Tau is a microtubule-binding protein that can receive various post-translational modifications (PTMs) including phosphorylation, methylation, acetylation, glycosylation, nitration, sumoylation and truncation. Hyperphosphorylation of tau is linked to its aggregation and the formation of neurofibrillary tangles (NFTs), which are a hallmark of Alzheimer's disease (AD). While more than 70 phosphorylation sites have been detected previously on NFT tau, studies of oligomeric and detergent-soluble tau in human brains during the early stages of AD are lacking. Here we apply a comprehensive electrochemiluminescence ELISA assay to analyze twenty-five different PTM sites as well as tau oligomerization in control and sporadic AD brain. The samples were classified as Braak stages 0-I, II or III-IV, cor2019-01-01T00:00:00Z2019 Dec2025-04-04T07:13:57.022Z2020-05-21T21:44:19ZS-EPMC68921783179612410.1186/s40478-019-0823-2